Revenue: As of FY2026 Q2, the actual value is USD 16.99 B, beating the estimate of USD 16.76 B.

EPS: As of FY2026 Q2, the actual value is USD 2.03, beating the estimate of USD 1.9107.

EBIT: As of FY2026 Q2, the actual value is USD 6.432 B.

The provided reference, a Form 8-K filing by AbbVie Inc. dated July 31, 2026, announces the issuance of a press release detailing the company’s financial results for the second quarter ended June 30, 2026. However, the actual financial metrics, operational data, cash flow information, or outlook/guidance are not included within this Form 8-K document itself. These details are furnished as Exhibit 99.1 to the report and incorporated by reference, which is not provided in the current text for analysis.